# China NMPA Inspection - Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. - October 19, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/guangxi-fucodisai-regenerative-medicine-engineering-co-ltd/e51a202e-a79e-4657-b6d0-8da818a1d0ad/
Source feed: China

> China NMPA unannounced inspection for Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. published October 19, 2020. The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of cosmetics manufacturers in October 2020, adhering to the

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement of the Results of Unannounced Inspections of Cosmetic Manufacturers in Guangxi Zhuang Autonomous Region (Issue 5, 2020)
- Company Name: Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd.
- Publication Date: 2020-10-19
- Product Type: cosmetics
- Summary: The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of cosmetics manufacturers in October 2020, adhering to the "Key Points for Cosmetic Production License Inspection" regulatory framework. These inspections, part of the 2020 regional supervision work plan, identified several non-compliances across four companies. Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd., inspected on October 12, 2020, lacked a pest control management system, related records, and complete original inspection and storage environment records, requiring rectification within a specified timeframe. Guangxi Jinxiutang Biotechnology Co., Ltd., inspected on October 15, 2020, failed to provide complete batch production records and had finished product inspection reports missing inspector/reviewer signatures and dates, also receiving a rectification order. Guangxi Qingcuitang Biotechnology Co., Ltd., inspected on October 13, 2020, presented more severe issues including an unappointed quality manager, failure to provide quality management system documents, absent quality management department signatures for product release in batch records, and inadequate environmental control during production. This resulted in an order for production suspension and rectification. Lastly, Nanning Minglu Medical and Health Products Co., Ltd., inspected on October 14, 2020, was cited for unlabeled materials and intermediate products, lack of verification signatures in the weighing process, and no records for handling unqualified packaging materials, necessitating rectification within a time limit. All findings indicate a need for enhanced adherence to established cosmetic production standards.

Company: https://www.globalkeysolutions.net/companies/guangxi-fucodisai-regenerative-medicine-engineering-co-ltd/ab8705fc-ca1c-4fdd-8f80-aff0b89b8795/